QuidelOrtho Recognized with Three Awards in 2025 IMV ServiceTrak™
Awards:
Chemistry
Best overall system performance
Integrated Systems
Best overall system performance
Best overall service
Top Rankings:
QuidelOrtho received top rankings in several key categories for Integrated Systems, including:
#1 Overall Net Promoter Score (NPS) by Manufacturer
#1 Overall Manufacturer Performance
#1 Overall Service Engineer Performance
#1 Overall Training Performance
QuidelOrtho invested in initiatives focused on what customers value most, driving significant advances in reliability, product quality and service. This commitment delivered a 17-point increase in NPS, the largest gain in the category, reflecting higher customer loyalty and satisfaction.
Learn how QuidelOrtho prioritizes customers' beliefs and values to deliver solutions.
These awards and rankings showcase QuidelOrtho's comprehensive approach to enhancing both product and service in clinical diagnostics. A key part of this success has been investing in employee development through specialized customer experience training, fueling continued progress and stronger relationships with customers.
QuidelOrtho remains committed to ongoing innovation and delivering smart, customer-focused solutions that elevate laboratory efficiency and outcomes.
Key Quotes:
Karen Taylor, Senior Vice President, Customer Experience, QuidelOrtho
"We're honored to be recognized with three awards and top rankings in this year's IMV ServiceTrak Awards, but even more so, we're grateful to our customers for their ongoing trust and collaboration. These results reflect their feedback and our shared commitment to improving outcomes together. Our QuidelOrthoCQ™ solutions are designed to give customers the freedom to focus on what matters most. We'll continue listening and evolving to better support their success."
Additional Resources:
Listen to Karen Taylor's Repertoire Magazine Interview: Freedom to Focus: How QuidelOrthoCQ is creating delightful customer experiences
About IMV ServiceTrakThe IMV ServiceTrak Clinical Laboratory Awards are the result of independent market research assessing manufacturer performance in the in-vitro diagnostics space. IMV's annual report represents an independent analysis of customer satisfaction with instrument manufacturers, system performance and service received.
IMV's ServiceTrak Clinical Laboratory Awards are based on feedback from laboratory testing professionals in 1,800 clinical testing locations, representing 4,100 instruments. For over 25 years, IMV ServiceTrak has provided independent analysis of service trends and manufacturer ratings in laboratory diagnostics.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a global provider of innovative diagnostic testing solutions. From infectious diseases to cardiac biomarkers to women's health, QuidelOrtho transforms the power of diagnostics into a healthier future through science, innovation and accessibility. Learn more at www.quidelortho.com.
Investor Contact:
Media Contact:
Juliet Cunningham
D. Nikki Wheeler
Vice President, Investor Relations
Senior Director, Corporate
IR@QuidelOrtho.com
CommunicationsMedia@QuidelOrtho.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-recognized-with-three-awards-in-2025-imv-servicetrak-302516577.html
SOURCE QuidelOrtho Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
10 hours ago
- Time Business News
Ford: A Timeless Journey of Innovation, Strength, and Legacy
Few automotive brands carry the weight of history and innovation quite like Ford. It's more than just a company—it's a global icon, a symbol of progress, and a trusted name woven into the fabric of modern society. From the roaring engines of classic muscle cars to the silent hum of next-gen electric vehicles, Ford represents a legacy of freedom, reliability, and bold vision. For over a century, Ford has stood as a pioneer of both industry and imagination. Whether you're cruising down a coastal highway or hauling heavy loads across rugged terrain, Ford drives dreams forward—generation after generation. In 1903, a visionary named Henry Ford changed the course of transportation forever. He didn't just build cars—he built a movement. Ford believed that every individual, not just the wealthy, deserved access to mobility. This dream gave birth to the Model T, the car that put the world on wheels. What truly set Ford apart was the introduction of the moving assembly line in 1913. This groundbreaking innovation reduced manufacturing time, lowered costs, and allowed Ford to pay workers fair wages. It wasn't just a business decision—it was a social revolution. In many ways, Ford helped shape the modern middle class. What began in a modest Detroit workshop has grown into a global powerhouse. Today, Ford operates in more than 100 countries, with production plants, design studios, and dealerships around the globe. Each region sees its piece of the Ford experience—from compact cars in Asia to heavy-duty trucks in the Americas. But despite its global presence, Ford maintains its core identity: durability, innovation, and customer trust. That's why you'll see a Ford at a dusty construction site in Texas, a rally course in Kenya, or a city street in London—proving that Ford is truly built for every road, every driver. Ford's legacy is one of constant reinvention. While honoring its heritage, Ford has always had one foot in the future. Recent years have seen an incredible wave of technological innovation: Ford Co-Pilot360™ : A suite of advanced driver-assist features like automatic emergency braking, blind-spot monitoring, and lane-keeping systems—all designed to keep drivers safer and more confident behind the wheel. : A suite of advanced driver-assist features like automatic emergency braking, blind-spot monitoring, and lane-keeping systems—all designed to keep drivers safer and more confident behind the wheel. SYNC Infotainment System : Voice-activated technology, navigation, Apple CarPlay, Android Auto, and cloud-connected features bring cutting-edge tech to your fingertips. : Voice-activated technology, navigation, Apple CarPlay, Android Auto, and cloud-connected features bring cutting-edge tech to your fingertips. FordPass™ App: A smartphone gateway to remote start, lock/unlock, locate your vehicle, schedule service appointments, and more. Innovation isn't a trend for Ford—it's part of its DNA. The automotive world is shifting, and Ford is leading the charge—literally. With a multi-billion-dollar investment in electric vehicle (EV) infrastructure, Ford is committed to a cleaner, brighter, and more efficient future. Mustang Mach-E : This all-electric SUV combines the soul of the iconic Mustang with the sustainability of the future's sleek, silent—and pure adrenaline. : This all-electric SUV combines the soul of the iconic Mustang with the sustainability of the future's sleek, silent—and pure adrenaline. F-150 Lightning : The beloved pickup, reborn as an all-electric powerhouse. With dual motors, instant torque, and even the ability to power your home, it's redefining what a truck can be. : The beloved pickup, reborn as an all-electric powerhouse. With dual motors, instant torque, and even the ability to power your home, it's redefining what a truck can be. E-Transit Van: Designed for commercial use, this EV delivers zero-emissions transport without sacrificing payload or functionality. Ford is more than ready for tomorrow—it's building it today. If there's one phrase that perfectly defines Ford's spirit, it's 'Built Ford Tough.' Ford's lineup of trucks—especially the iconic F-Series—has been trusted by hard-working individuals for generations. The Ford F-150, in particular, is the best-selling vehicle in the United States for over 40 years. It's not just popular; it's legendary. With exceptional towing capacity, military-grade aluminum alloy construction, hybrid powertrain options, and rugged styling, it's built for those who demand power, performance, and perseverance. Ford understands that authentic leadership means protecting the world we share. That's why sustainability is a core focus: Committed to carbon neutrality by 2050 Manufacturing plants powered by renewable energy Use of recycled and sustainable materials in new vehicle production in new vehicle production Innovation in battery technology and EV charging infrastructure Ford isn't just adapting to environmental responsibility—it's setting the standard. For millions, owning a Ford is more than transportation—it's a relationship. It's the car that taught your teenager to drive, the truck that hauled your first home, the Mustang that turned heads, or the van that took your family on summer road trips. Ford vehicles are in the photos of your memories, in the heart of your journeys, and in the conversations passed down from one generation to the next. This emotional bond is what makes Ford timeless. From Steve McQueen's 1968 Mustang in Bullitt to Will Smith's futuristic Ford GT in I, Robot , Ford has become a pop culture icon. Songs, movies, video games—you'll find Ford roaring across them all. That's because Ford is more than a car—it's a character, a symbol, and a source of inspiration. With over a century of legacy, innovation, and trust, Ford remains a brand like no other. It's a company that stays true to its roots while courageously reimagining the future. Whether you're a die-hard Mustang enthusiast, a rugged F-150 driver, or a first-time EV owner, Ford welcomes you with open arms—and an open road. Because with Ford, the drive never ends. TIME BUSINESS NEWS
Business Wire
11 hours ago
- Business Wire
Align Technology President and CEO Joe Hogan Personally Purchases $1 Million of Align's Common Stock
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Joe Hogan, Align Technology president and CEO, has personally purchased approximately $1 million of Align's common stock. Since his last sale of Align common stock in 2021, Mr. Hogan has purchased approximately $8 million of Align common stock 1. 'This purchase reflects my continuing confidence in the long-term value of Align and our commitment to increasing shareholder value by balancing investments to drive growth and continuing to invest with discipline in the areas that will define our future,' said Joe Hogan, president and CEO. 'We are excited about our next-generation technologies and treatment platforms that meet today's patient expectations for fast, effective, and personalized treatment while also providing value and growth opportunities for our doctor customers. We believe that these innovations are not only improving outcomes in Invisalign practices but also expanding our addressable market and strengthening our competitive differentiation.' Continued Hogan, 'While we believe that the macroeconomic uncertainty will likely persist into the near future, we are confident in our ability to adapt and lead. Our long-term strategic initiatives and opportunities remain intact, as does our commitment to focused execution on transforming treatment for doctors and patients.' 1 Valued based on the purchase price of Align common stock at the time of each purchase. About Align Technology Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 286.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform, and iTero Lumina are trademarks of Align Technology, Inc.
Miami Herald
17 hours ago
- Miami Herald
Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, August 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S. Access the interviews in their entirety at: CLDI: In an exclusive interview, Eric Poma, Ph.D., CEO of Calidi Biotherapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss Calidi's pioneering approach to precision genetic medicine, enabled by its proprietary RedTail platform-an engineered, systemically delivered viral therapy designed to reach metastatic sites and deliver genetic medicines to treat tumors. The platform cloaks potent genetic payloads, such as IL-15 superagonist, within a human-derived envelope, allowing the virus to evade immune detection and circulate throughout the body. Preclinical data showcased at AACR and ASCO demonstrated that a single dose of Calidi's lead candidate, CLD-401, not only eliminated metastatic tumors but also primed immune memory, offering the potential to prevent recurrence. With its scalable, non-integrating viral backbone and ability to deliver multiple genetic payloads, RedTail positions Calidi to address a vast oncology market projected to exceed $560 billion by 2033. The company is advancing toward IND filing in 2026, while exploring strategic pharma partnerships to support global commercialization. Calidi's capital-efficient business model, strengthened balance sheet, and next-generation pipeline targeting both cancer and autoimmune diseases highlight its strong potential to deliver value to shareholders. Dr. Steven Quay, CEO of Atossa Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss Atossa's strategic approach to redefining breast cancer treatment through its lead clinical candidate, (Z)-endoxifen - a next-generation SERM with best-in-class potential. With a focus on metastatic breast cancer, where current therapies often fall short, Atossa is advancing multiple Phase 2 studies that demonstrate strong clinical activity, improved tolerability, and a favorable safety profile. The presentation will highlight recent progress across key development programs, upcoming milestones, and how the Company's differentiated science and capital-efficient model are designed to deliver both clinical impact and long-term shareholder value. CLDI and ATOS are clients of RedChip Companies. Please read our full disclosure at About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease. The company's proprietary Redtail platform represents a decade of development and expertise in designing viral vectors that can evade immune detection allowing for systemic delivery and distal sites of disease in oncology and, potentially, other indications. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations. The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit About Atossa Therapeutics Atossa Therapeutics, Inc. (Nasdaq:ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company's lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit About RedChip Companies RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. RedChip also offers RedChat™, a proprietary AI-powered chatbot that analyzes SEC filings and corporate disclosures for all Nasdaq and NYSE-listed companies, giving investors instant, on-demand insights. To learn more about RedChip's products and services, please visit: "Discovering Tomorrow's Blue Chips Today"™ Follow RedChip on LinkedIn: Follow RedChip on Facebook: Follow RedChip on Instagram: Follow RedChip on Twitter: Follow RedChip on YouTube: Follow RedChip on Rumble: Subscribe to our Mailing List: Contact: Dave GentryRedChip Companies Inc.1-407-644-4256info@ SOURCE: RedChip Companies, Inc.
